ARS Pharmaceuticals (SPRY) Net Margin (2022 - 2026)
ARS Pharmaceuticals (SPRY) posted Net Margin of 422.96% for Q1 2026, down 172.98% sequentially from 154.94% in Q4 2025, and up 4532.0% YoY from 9.13% in Q1 2025.
ARS Pharmaceuticals (SPRY) Net Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Net Margin for 5 years, with the latest figure at 422.96% in Q1 2026.
- Quarterly Net Margin rose 4532.0% year-over-year to 422.96% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 479.56% (down 26036.0% YoY) and the FY2025 annual result came in at 203.25%, down 21223.0% from the prior year.
- Net Margin fell to 422.96% in Q1 2026 per SPRY's latest filing, from 154.94% in the prior quarter.
- Over five years, Net Margin peaked at 54.59% in Q4 2024 and troughed at 382009450.0% in Q2 2023.
- A 5-year average of 44544778.06% and a median of 1749.47% in 2022 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2024: Net Margin tumbled 2000000000 bps in 2023, then surged 2000000000 bps in 2024.
- Over 5 years, Net Margin stood at 8018.52% in 2022, then sank by 4763990 bps to 382009450.0% in 2023, then jumped by 100 bps to 54.59% in 2024, then tumbled by 384 bps to 154.94% in 2025, then tumbled by 173 bps to 422.96% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 422.96%, 154.94%, and 347.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -287.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -287.23% |
| Mar 31, 2026 | -422.96% |
| Dec 31, 2025 | -154.94% |
| Sep 30, 2025 | -347.61% |
| Jun 30, 2025 | -1,414.22% |
| Mar 31, 2025 | -468.28% |
| Dec 31, 2024 | 54.59% |
| Sep 30, 2024 | -7,514.89% |
| Jun 30, 2024 | -13,481.40% |
| Jun 30, 2023 | -382,009,450.00% |
| Mar 31, 2023 | -197,036,230.00% |
| Sep 30, 2022 | -8,018.52% |
| Jun 30, 2022 | -2,917.03% |
| Mar 31, 2022 | -1,749.47% |